港股異動 | 獲券商唱好 康寧傑瑞(9966.HK)6連升欲創新高價
格隆匯6月24日丨康寧傑瑞(9966.HK)續升6.3%,6日連漲近20%,高見24.7港元欲再創歷史新高價,總市值達230億港元。華創證券首予康寧傑瑞製藥-B“推薦”評級,公司KN046生存數據驚豔,大適應症進度領先。報吿提到,KN026胃癌數據優異,HER2雙抗潛力巨大。與同類產品對比,KN026在有效性指標有望優於ZW25和RC48,安全性指標有望顯著優於DS-8201,KN026有望成為HER2領域新一代的重磅藥物。該行又指公司未來研發管線價值有望不斷提升。基於領先的研發水平,康寧傑瑞打造了一條具有顯著差異化和全球競爭力的產品管線。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.